默克从Blackstone得到700万元 在15次试验中 推进癌症药物的抗TMT 保持全面控制 Merck gets $700M from Blackstone to advance cancer drug sac-TMT in 15 trials, keeping full control.

Merck已经从黑石生命科学获得7亿美元,用于推进其实验性癌症药物 -- -- 盐酸盐(sac-TMT) -- -- 在乳腺癌、内脏癌、肺癌和其他癌症的15次晚期试验中针对TROP2蛋白质。 Merck has secured $700 million from Blackstone Life Sciences to advance its experimental cancer drug sacituzumab tirumotecan (sac-TMT), which targets the TROP2 protein in 15 late-stage trials across breast, endometrial, lung, and other cancers. 这笔资金将通过2026年支付,用于支持发展费用,Blackstone有资格获得美国销售的低到中位的单位数使用费,如果sac-TMT获得三线阴性乳腺癌一线治疗的批准。 The funding, to be disbursed through 2026, supports development costs, with Blackstone eligible for low-to-mid single-digit royalties on U.S. sales if sac-TMT gains approval for first-line treatment of triple-negative breast cancer. Merck完全控制毒品的发展、制造和商业化,这项交易不影响它与四川Kelun-Biotech的现有伙伴关系。 Merck retains full control over the drug’s development, manufacturing, and commercialization, and the deal does not affect its existing partnership with Sichuan Kelun-Biotech.